2023
Laryngeal dystonia: Phenomenology, genetics, and management
Blitzer A, Kohli N. Laryngeal dystonia: Phenomenology, genetics, and management. Toxicon 2023, 233: 107258. PMID: 37647998, DOI: 10.1016/j.toxicon.2023.107258.Peer-Reviewed Original ResearchConceptsLaryngeal dystoniaMovement disordersOnabotulinum toxin APosterior cricoarytenoid muscleRare movement disorderTask-specific movement disorderEndoscopic findingsCricoarytenoid muscleBotulinum toxinAbnormal movementsToxin AThyroarytenoid muscleDystoniaAbductor musclesPatientsTreatment resultsDisordersNormal functionVocal foldsMuscleToxinSymptomsIncidenceLarynxFirst use
2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects